Skip to main content
OpenTrials
Completed

NCT Number: NCT00337766

Desmopressin in Cardiac Surgery

Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products.

Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • undergoing cardiac surgery
  • excessive bleeding

Exclusion criteria

  • age<18 y
  • not signing written consent

Treatment and study plan

Desmopressin (DDAVP)

Drug

Placebo

Drug

Primary outcomes

  1. Reduce transfusions

Secondary outcomes

  1. Reduced bleeding

  2. Reduce time on mechanical ventilation

  3. Reduced ICU and Hospital stay

  4. Reduced mortality

Sponsors and collaborators

Lead sponsor

Università Vita-Salute San Raffaele

Other

Registry information

Official study title

Efficacy of Desmopressin (1-deamin0-8-D-arginine-vasopressin) in Reducing Active Microvascular Bleeding After Cardiac Surgery

Important dates

Study start
2006
Primary completion
2009
Study completion
2010
First posted
Jun 16, 2006
Registry last updated
Oct 21, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.